Emerging nanoparticle-based therapies for pancreatic cancer: Current clinical landscape [0.03%]
基于纳米粒子的胰腺癌新兴疗法：当前临床应用现状
Ainara Salgado,Sara Zalba,Juan José Lasarte et al.
Ainara Salgado et al.
Pancreatic cancer, particularly ductal adenocarcinoma (PDAC) is one of the most aggressive and lethal subtypes due to late diagnosis, the absence of early biomarkers, and the presence of a complex tumor microenvironment (TME). This TME is c...
Overcoming barriers and shaping the future: Challenges and innovations in nucleic acid therapies for Glioblastoma [0.03%]
突破障碍塑造未来：胶质母细胞瘤核酸治疗的挑战与创新
Alaa Zam,Nadia Rouatbi,Adam A Walters et al.
Alaa Zam et al.
Glioblastoma (GBM) is the most aggressive and treatment-resistant primary brain tumor in adults. Conventional therapies offer limited benefit due to the tumor's heterogeneity, invasive nature, and the presence of the blood-brain barrier, wh...
Integrating PROTAC-based targeted protein degradation with nanodelivery systems to overcome cancer therapeutic resistance [0.03%]
基于靶向蛋白降解的PROTAC与纳米递送系统结合以克服癌症治疗耐药性
Xinyu Gou,Shi He,Bilan Wang et al.
Xinyu Gou et al.
Tumor drug resistance is a major challenge in cancer treatment, as traditional chemotherapeutic agents and small molecule inhibitors often become ineffective in targeting tumors due to drug resistance. Proteolysis Targeting Chimeras (PROTAC...
Exploiting colloidal drug aggregation for drug delivery: From promise to prediction using computational tools [0.03%]
利用计算工具实现药物输送中的胶体药物聚集：从前景到预测
Kai V Slaughter,Xiang Olivia Li,Molly S Shoichet
Kai V Slaughter
Colloidal drug aggregates are amorphous nanoparticles formed by the self-assembly of hydrophobic small molecule drugs. They can be leveraged as drug-rich nanoparticle formulations for drug delivery. However, it is difficult to predict which...
Changchong Chen,Zixuan Zhao,Dong Hua Seah et al.
Changchong Chen et al.
Spatial heterogeneity is a fundamental feature of the tumor microenvironment, characterized by structured variations in cellular composition, phenotypic states, extracellular matrix (ECM) organization, and biochemical and biophysical gradie...
Clinical translation and landscape of superparamagnetic iron oxide nanoparticles [0.03%]
超顺磁性铁氧化物纳米颗粒的临床转化和研究现状
Yanchen Li,Roman A Barmin,Rui Zhang et al.
Yanchen Li et al.
Since their initial clinical approval as liver imaging agents nearly three decades ago, superparamagnetic iron oxide nanoparticles (SPIONs) have evolved beyond diagnostic imaging to include also therapeutic and theranostic applications. The...
Gas-based therapeutics and delivery platforms in cancer immunotherapy [0.03%]
癌症免疫治疗中的气体靶向治疗及输送平台疗法研究进展
Van-Anh Thi Nguyen,Chieh-Cheng Huang,Yunching Chen
Van-Anh Thi Nguyen
Gas-based therapeutics are emerging as a promising strategy in cancer immunotherapy. Small gaseous signaling molecules such as nitric oxide (NO), carbon monoxide (CO), hydrogen sulfide (H2S), and oxygen (O2) efficiently penetrate tumor tiss...
Recent advances in numerical simulation of magnetically guided drug delivery systems and applications [0.03%]
磁控药物传输系统数值模拟研究进展及应用实例
Zhenyang Xu,Tayebeh Mousavi,Xiaoli Liu et al.
Zhenyang Xu et al.
Magnetically guided drug delivery (MGDD) employs magnetic forces acting on magnetically responsive drug delivery systems (DDS) to direct therapeutic agents toward diseased regions, thereby enhancing local drug accumulation while minimising ...
Perspectives and trends in gas delivery systems based on ultrasound responsive nanomaterials for cancer therapy [0.03%]
基于超声响应纳米材料的癌症治疗供气系统的新进展及未来趋势
Jooho Moon,Hanhee Cho,Jeonghun Yu et al.
Jooho Moon et al.
Gas-based therapeutic strategies (e.g., nitric oxide and carbon dioxide delivery) have shown promising potential for modulating the tumor microenvironment and enhancing anticancer efficacy. However, their clinical translation is limited by ...
GMP-compliant manufacturing of iPSC-derived therapeutic cell products: Technologies, applications, risks and limitations [0.03%]
符合GMP规范的诱导多能干细胞来源治疗性细胞产品的生产工艺：技术、应用、风险及局限性
Alexandra Haase,Arjang Ruhparwar,Ulrich Martin
Alexandra Haase
The development of induced pluripotent stem cells (iPSCs) has transformed the field of regenerative medicine. However, to use iPSCs for therapeutic applications, iPSC-based products must be produced under Good Manufacturing Practice (GMP) c...